Raising the bar for randomized trials involving artificial intelligence: the SPIRIT-artificial intelligence and CONSORT-artificial intelligence guidelines
Taylor, Matthew Liu, Xiaoxuan Denniston, Alastair Esteva, Andre Ko, Justin Daneshjou, Roxana Chan, An-Wen
Taylor, Matthew
Liu, Xiaoxuan
Denniston, Alastair
Esteva, Andre
Ko, Justin
Daneshjou, Roxana
Chan, An-Wen
Abstract
Artificial intelligence (AI)-based applications have the potential to improve the quality and efficiency of patient care in dermatology. Unique challenges in the development and validation of these technologies may limit their generalizability and real-world applicability. Before the widespread adoption of AI interventions, randomized trials should be conducted to evaluate their efficacy, safety, and cost effectiveness in clinical settings. The recent Standard Protocol Items: Recommendations for Interventional Trials-AI extension and Consolidated Standards of Reporting Trials-AI extension guidelines provide recommendations for reporting the methods and results of trials involving AI interventions. High-quality trials will provide gold standard evidence to support the adoption of AI for the benefit of patient care.
MIDER Authors
Citations
Altmetric:
Date
2021-03-22
Type
Article
Subject
Dermatology
Collections
Citation
Taylor M, Liu X, Denniston A, Esteva A, Ko J, Daneshjou R, Chan AW; SPIRIT-AI and CONSORT-AI Working Group. Raising the Bar for Randomized Trials Involving Artificial Intelligence: The SPIRIT-Artificial Intelligence and CONSORT-Artificial Intelligence Guidelines. J Invest Dermatol. 2021 Sep;141(9):2109-2111. doi: 10.1016/j.jid.2021.02.744. Epub 2021 Mar 22
Journal / Source Title
Journal of Investigative Dermatology
DOI
10.1016/j.jid.2021.02.744
PMID
33766511
Publisher
Elsevier
Publisher’s URL
https://www.jidonline.org/